Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 9
Submit an article Journal homepage
451
Views
34
CrossRef citations to date
0
Altmetric
Drug Evaluations

Interferon-β treatment for relapsing multiple sclerosis

Bianca Weinstock-Guttman Associate Professor of Neurology, Director of Baird MS Center and Pediatric MS Center University at Buffalo, State University of New York, The Jacobs Neurological Institute, Department of Neurology, 100 High Street, Buffalo, NY 14203, USA +1 716 859 7514; +1 716 859 7573; [email protected]
, MD,
Murali Ramanathan State University of New York, Department of Pharmaceutical Sciences, Buffalo, NY, USA
&
Robert Zivadinov University at Buffalo, State University of New York, Buffalo Neuroimaging Analysis Center, Department of Neurology, Buffalo, NY, USA
Pages 1435-1447 | Published online: 11 Aug 2008

Bibliography

  • Rudick RA, Cohen JA, Weinstock-Guttman B, et al. Management of multiple sclerosis. N Engl J Med 1997;337:1604-11
  • Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999;53:1698-704
  • Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17
  • Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-61
  • Frohman EM, Racke MK, Raine CS. Multiple sclerosis–the plaque and its pathogenesis. N Engl J Med 2006;354:942-55
  • Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11
  • Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45(7):1268-76
  • Dhib-Jalbut S. Glatiramer acetate (Copaxone) therapy for multiple sclerosis. Pharmacol Ther 2003;98(2):245-55
  • Chen M, Conway K, Johnson KP, et al. Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6-years. J Neurol Sci 2002;201(1-2):71-7
  • Weber MS, Prod'homme T, Youssef S, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007;13:935-43
  • Lublin FD, Cutter GR, Elfont R. A trial to assess the safety of combining therapy with interferon β-1a and glatiramer acetate in patients with relapsing MS. Neurology 2001;56:A148
  • Rudick RA, Sandrock A. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004;4:571-80
  • Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
  • Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
  • Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81
  • Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 2005;353:432-3
  • Alvarez-Cermeno JC, Masjuan J, Villar LM. Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis. N Engl J Med 2005;353:1744-6; author reply 1744-6
  • Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-33
  • Goodin D. The return of natalizumab: weighing benefit against risk. Lancet Neurol 2006;5:375-7
  • Chadha K, Weinstock-Guttman B, Zivadinov R, et al. Interferon inhibitory activity in patients with multiple sclerosis. Arch Neurol 2006;63:1579-84
  • Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998;50:1266-72
  • Santos R, Weinstock-Guttman B, Tamano-Blanco M, et al. Dynamics of interferon-β modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-β neutralizing antibodies. J Neuroimmunol 2006;176:125-33
  • Rudick RA, Lee JC, Simon J, et al. Defining interferon β response status in multiple sclerosis patients. Ann Neurol 2004;56:548-55
  • Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-60
  • Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40
  • Brown BA, Kantesaria PP, McDevitt LM. Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann Pharmacother 2007;41:1660-8
  • Miron VE, Jung CG, Kim HJ, et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008;63:61-71
  • Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88
  • Ransohoff RM. Cellular responses to interferons and other cytokines: the JAK-STAT paradigm. N Engl J Med 1998;338:616-8
  • Stark GR, Kerr IM, Williams BR, et al. How cells respond to interferons. Ann Rev Biochem 1998;67:227-64
  • Rani MR, Foster GR, Leung S, et al. Characterization of β-R1, a gene that is selectively induced by interferon beta (IFN-β) compared with IFN-α. J Biol Chem 1996;271:22878-84
  • Abramovich C, Shulman LM, Ratovitski E, et al. Differential tyrosine phosphorylation of the IFNAR chain of the type I interferon receptor and of an associated surface protein in response to IFN-α and IFN-β. EMBO J 1994;13:5871-7
  • Platanias LC, Uddin S, Colamonici OR. Tyrosine phosphorylation of the α and β subunits of the type I interferon receptor. Interferon-β selectively induces tyrosine phosphorylation of an α subunit-associated protein. J Biol Chem 1994;269:17761-4
  • Ling PD, Warren MK, Vogel SN. Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages. J Immunol 1985;135:1857-63
  • Inaba K, Kitaura M, Kato T, et al. Contrasting effect of α/β- and γ-interferons on expression of macrophage Ia antigens. J Exp Med 1986;163:1030-5
  • Fertsch D, Schoenberg DR, Germain RN, et al. Induction of macrophage Ia antigen expression by rIFN-gamma and down-regulation by IFN-alpha/beta and dexamethasone are mediated by changes in steady-state levels of Ia mRNA. J Immunol 1987;139:244-9
  • Calabresi PA, Tranquill LR, Dambrosia JM, et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b. Ann Neurol 1997;41:669-74
  • Byskosh PV, Reder AT. Interferon β-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult Scler 1996;1:262-9
  • Hamamcioglu K, Reder AT. Interferon-β regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis. Mult Scler 2007;13:459-70
  • Goodin DS. Treatment of MS with human beta interferon. Int MS J 2005;12:96-108
  • Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
  • The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
  • Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-7
  • Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998;43:79-87
  • Jaber A, Driebergen R, Giovannoni G, et al. The Rebif new formulation story: it's not trials and error. Drugs R&D 2007;8:335-48
  • Ross TM, Martinez PM, Renner JC, et al. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 2004;151:66-77
  • Neuhaus O, Kieseier BC, Hartung HP. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J Neurol Sci 2007;259:27-37
  • Salmon P, Le Cotonnec JY, Galazka A, et al. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res 1996;16:759-64
  • Sturzebecher S, Maibauer R, Heuner A, et al. Pharmacodynamic comparison of single doses of IFN-β1a and IFN-β1b in healthy volunteers. J Interferon Cytokine Res 1999;19:1257-64
  • Fierlbeck G, Ulmer A, Schreiner T, et al. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma. J Interferon Cytokine Res 1996;16:777-81
  • Liberati AM, Garofani P, De Angelis V, et al. Double-blind randomized Phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously. J Interferon Res 1994;14:61-9
  • Munafo A, Trinchard-Lugan II, Nguyen TX, Buraglio M. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol 1998;5:187-93
  • Alam J, Goelz S, Rioux P, et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN β-1 a) products administered intramuscularly in healthy male and female volunteers. Pharm Res 1997;14:546-9
  • Wandinger KP, Sturzebecher CS, Bielekova B, et al. Complex immunomodulatory effects of interferon-β in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol 2001;50:349-57
  • Sturzebecher S, Wandinger KP, Rosenwald A, et al. Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis. Brain 2003;126:1419-29
  • Weinstock-Guttman B, Badgett D, Patrick K, et al. Genomic effects of IFN-β in multiple sclerosis patients. J Immunol 2003;171:2694-702
  • Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112(Pt 6):1419-28
  • Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112(Pt 1):133-46
  • Confavreux C, Vukusic S. Natural history of multiple sclerosis: implications for counselling and therapy. Curr Opin Neurol 2002;15:257-66
  • Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504
  • Stone LA, Frank JA, Albert PS, et al. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 1997;49:862-9
  • Zivadinov R, Reder A, Filippi M. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008;71(2):136-44
  • Frank JA, Richert N, Bash C, et al. Interferon-β-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. Neurology 2004;62:719-25
  • Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-β1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999;46:197-206
  • PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001;56:1628-36
  • Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-53
  • Zivadinov R, Locatelli L, Cookfair D, et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler 2007;13:490-501
  • Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1489-96
  • Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904
  • Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82
  • Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9
  • Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002;59:1496-506
  • Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60
  • Fisher E, Rudick RA, Cutter G, et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000;6:373-7
  • Miller DM, Rudick RA, Cutter G, et al. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol 2000;57:1319-24
  • Rudick RA, Cutter G, Baier M, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 2001;56:1324-30
  • Mikol DD, Barkhof F, PC. The REGARD trial: a randomized assessor blinded trial comparing interferon beta-1a and Glatiramer acetate in RR MS. 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Prague, Czech Republic, 2007. Available from: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=54436&XNSPRACHE_ID=2&XNKONGRESS_ID=63&XNMASKEN_ID=900 [Last accessed 18 July 2008]
  • Bayer Healthcare. BEYOND study: results do not support regulatory filing for Betaferon 500mcg. Available from: http://www.viva.vita.bayerhealthcare.com/index.php?id=36&tx_ttnews%5Btt_news%5D=12123&tx_ttnews%5BbackPid%5D=75&cHash=e6d4919620 [Last accessed 18 July 2008]
  • Wolanski L, Cook S, Skurnick J. Betaseron vs. Copaxone in MS with triple-dose gadolinium and 3-T MRI endpoints (BECOME): announcement of final primary outcome. 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Prague, Czech Republic, 2007. Available from: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=51545&XNSPRACHE_ID=2&XNKONGRESS_ID=63&XNMASKEN_ID=900 [Last accessed 18 July 2008]
  • Paolillo A, Pozzilli C, Giugni E, et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta. Eur J Neurol 2002;9:645-55
  • Patti F, Pappalardo A, Florio C, et al. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study. Acta Neurol Scand 2006;113:241-7
  • Koch-Henriksen N, Sorensen PS, Christensen T, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006;66:1056-60
  • Rice G. The significance of neutralizisng antibodies in patients with multiple sclerosis treated with interferon beta. Arch Neurol 2001;58:1297-8
  • Li D, Traboulsee A, Abdalla J, et al. Long-term observational follow-up of the PRISMS cohort: analysis of MRI lesion burden in RRMS patients treated with IFN beta-1a three times weekly (Rebif). Am Acad Neurol Abstr 2004;P02.118
  • Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92
  • Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86
  • Weinshenker BG. Databases in MS research: pitfalls and promises. Mult Scler 1999;5:206-11
  • Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-β-treated relapsing multiple sclerosis. Ann Neurol 2007;61:300-6
  • Vartanian T, Solberg Sorensen P, Rice G. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis. J Neurol 2004;251(Suppl 2):II25-30
  • Reske D, Walser A, Haupt WF, Petereit HF. Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment. Acta Neurol Scand 2004;109:66-70
  • Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65:33-9
  • Petkau AJ, White RA, Ebers GC, et al. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004;10:126-38
  • Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999;53:1622-7
  • Durelli L, Bongioanni MR, Ferrero B, et al. Interferon treatment for multiple sclerosis: autoimmune complications may be lethal. Neurology 1998;50:570-1
  • Yoshida EM, Rasmussen SL, Steinbrecher UP, et al. Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology 2001;56:1416
  • Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the β-interferons for MS: a comparison between the three products. Neurology 2004;62:628-31
  • Karni A, Abramsky O. Association of MS with thyroid disorders. Neurology 1999;53:883-5
  • Monzani F, Caraccio N, Meucci G, et al. Effect of 1-year treatment with interferon-β1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur J Endocrinol 1999;141:325-31
  • de Seze J, Canva-Delcambre V, Fajardy I, et al. Autoimmune hepatitis and multiple sclerosis: a coincidental association? Mult Scler 2005;11:691-3
  • Feng X, Petraglia AL, Chen M, et al. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 2002;129:205-15
  • Moreno-Otero R. Therapeutic modalities in hepatitis C: challenges and development. J Viral Hepat 2005;12:10-9
  • Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.